Manel Sabaté1, Sergio Cánovas2, Eulogio García3, Rosana Hernández Antolín3, Luis Maroto3, José María Hernández4, Juan H Alonso Briales4, Antonio J Muñoz García4, Enrique Gutiérrez-Ibañes5, Jorge Rodríguez-Roda5. 1. On behalf of the Working Group on Cardiac Catheterization and Interventional Cardiology (Sección de Hemodinámica y Cardiología Intervencionista) of the Spanish Society of Cardiology (Sociedad Española de Cardiología); Hospital Universitari Clínic, IDIBAPS, Barcelona, Spain. Electronic address: masabate@clinic.ub.es. 2. On behalf of the Spanish Society of Thoracic-Cardiovascular Surgery (Sociedad de Cirugía Torácica-Cardiovascular); Servicio de Cirugía Cardiaca, Hospital General Universitario de Valencia, Valencia, Spain. 3. Servicio de Cardiología; Unidad de Cardiología Intervencionista y Servicio de Cirugía Cardiaca, Hospital Universitario Clínico San Carlos, Madrid, Spain. 4. Servicio de Cardiología, Hospital Clínico Virgen de la Victoria, Málaga, Spain. 5. Servicio de Cardiología; Unidad de Cardiología Intervencionista y Servicio de Cirugía Cardiaca, Hospital Gregorio Marañón, Madrid, Spain.
Abstract
INTRODUCTION AND OBJECTIVES: The treatment of severe symptomatic aortic stenosis has been revolutionized by the technique of transcatheter valve replacement. The purpose of this study was to present the outcomes and predictors of mortality in patients enrolled between 2010 and 2011 in the Transcatheter Aortic Valve Replacement National Registry. METHODS: We collected 131 preprocedural, 31 periprocedural, and 76 follow-up variables, and analyzed the immediate implant success rate, the 30-day safety endpoint, and all-cause 30-day and mid-term (mean follow-up, 244 days) mortality. RESULTS: From January 2010 to December 2011, a total of 1416 patients were included: 806 with Edwards valves and 610 with CoreValves. The implant success and 30-day mortality rates were 94% and 8%, respectively, without differences between types of valves and approaches. The 30-day safety endpoint and mid-term mortality rates were 14% and 16%, respectively, which were also similar between groups. The presence of comorbidities (renal failure, peripheral vascular disease, ejection fraction, and atrial fibrillation), the need for conversion to surgery, and at least moderate aortic regurgitation after transcatheter aortic valve implantation were identified as independent predictors of in-hospital and mid-term mortality. CONCLUSIONS: The prognosis of valve implant patients could be improved by including comorbidities in patient selection and by minimizing the degree of residual aortic regurgitation to optimize the results of the procedure.
INTRODUCTION AND OBJECTIVES: The treatment of severe symptomatic aortic stenosis has been revolutionized by the technique of transcatheter valve replacement. The purpose of this study was to present the outcomes and predictors of mortality in patients enrolled between 2010 and 2011 in the Transcatheter Aortic Valve Replacement National Registry. METHODS: We collected 131 preprocedural, 31 periprocedural, and 76 follow-up variables, and analyzed the immediate implant success rate, the 30-day safety endpoint, and all-cause 30-day and mid-term (mean follow-up, 244 days) mortality. RESULTS: From January 2010 to December 2011, a total of 1416 patients were included: 806 with Edwards valves and 610 with CoreValves. The implant success and 30-day mortality rates were 94% and 8%, respectively, without differences between types of valves and approaches. The 30-day safety endpoint and mid-term mortality rates were 14% and 16%, respectively, which were also similar between groups. The presence of comorbidities (renal failure, peripheral vascular disease, ejection fraction, and atrial fibrillation), the need for conversion to surgery, and at least moderate aortic regurgitation after transcatheter aortic valve implantation were identified as independent predictors of in-hospital and mid-term mortality. CONCLUSIONS: The prognosis of valve implant patients could be improved by including comorbidities in patient selection and by minimizing the degree of residual aortic regurgitation to optimize the results of the procedure.
Authors: R Jansen; A M Wind; M J Cramer; F Nijhoff; P Agostoni; F Z Ramjankhan; W J Suyker; P R Stella; S A J Chamuleau Journal: Int J Cardiovasc Imaging Date: 2018-03-10 Impact factor: 2.357
Authors: Giuseppe Tarantini; Paola A M Purita; Augusto D'Onofrio; Chiara Fraccaro; Anna Chiara Frigo; Gianpiero D'Amico; Luca Nai Fovino; Marta Martin; Francesco Cardaioli; Mostafa R A Badawy; Massimo Napodano; Gino Gerosa; Sabino Iliceto Journal: Ann Cardiothorac Surg Date: 2017-09
Authors: José-Luis López-Sendón; José Ramón González-Juanatey; Fausto Pinto; José Cuenca Castillo; Lina Badimón; Regina Dalmau; Esteban González Torrecilla; José Ramón López Mínguez; Alicia M Maceira; Domingo Pascual-Figal; José Luis Pomar Moya-Prats; Alessandro Sionis; José Luis Zamorano Journal: Eur Heart J Date: 2015-10-21 Impact factor: 29.983